Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc.（ARQT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ARQT · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
82
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Arcutis Biotherapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ARQT 季度内部人买卖趋势
ARQT 内幕交易卖出 · ARQT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ARQT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ARQT 高管卖出股份 · ARQT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 11, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale | 435 | $9K | Form 4 |
| May 11, 2026 | Burnett Patrick See Remarks | Sale | 222 | $5K | Form 4 |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale | 7,372 | $172K | Form 4 |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale | 884 | $21K | Form 4 |
| May 4, 2026 | Burnett Patrick See Remarks | Sale | 684 | $16K | Form 4 |
| May 4, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale | 1,341 | $32K | Form 4 |
| May 4, 2026 | Watanabe Todd See Remarks · Director | Sale | 3,172 | $75K | Form 4 |
| May 1, 2026 | Welgus Howard G. Director | Sale | 7,144 | $164K | Form 4 |
| Apr 1, 2026 | Welgus Howard G. Director | Sale | 10,000 | $239K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Option | 12,220 | $92K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Option | 27,052 | $233K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Sale | 39,272 | $997K | Form 4 |
| Mar 2, 2026 | Welgus Howard G. Director | Sale | 10,000 | $257K | Form 4 |
| Feb 27, 2026 | Edwards Larry Todd See Remarks | Award | 30,000 | — | Form 4 |
| Mar 2, 2026 | Edwards Larry Todd See Remarks | Sale | 3,584 | $90K | Form 4 |
| Mar 2, 2026 | Edwards Larry Todd See Remarks | Sale | 103 | $3K | Form 4 |
| Feb 27, 2026 | Watanabe Todd See Remarks · Director | Award | 102,000 | — | Form 4 |
| Mar 2, 2026 | Watanabe Todd See Remarks · Director | Sale | 36,281 | $913K | Form 4 |
| Mar 2, 2026 | Watanabe Todd See Remarks · Director | Sale | 1,068 | $28K | Form 4 |
| Feb 27, 2026 | Matsuda Masaru See Remarks | Award | 37,000 | — | Form 4 |
| Feb 27, 2026 | Matsuda Masaru See Remarks | Sale | 3,325 | $93K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 6,553 | $165K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 193 | $5K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 1,987 | $51K | Form 4 |
| Feb 27, 2026 | Vairavan Latha SVP Chief Financial Officer | Award | 27,000 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ARQT 内幕交易
ARQT 内幕交易
Arcutis Biotherapeutics, Inc.（ARQT）内幕交易数据来源于公司内部人（包括Burnett Patrick (See Remarks), Matsuda Masaru (See Remarks), Watanabe Todd (See Remarks · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。ARQT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Arcutis Biotherapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ARQT 内幕交易 · 5个问题Arcutis Biotherapeutics, Inc.（ARQT）的内部人包括高管和董事，如Burnett Patrick (See Remarks), Matsuda Masaru (See Remarks), Watanabe Todd (See Remarks · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026